文献速递乳腺癌

FAST-Forward:乳腺癌1周与3周大分割放疗10年疗效及腋窝亚组5年结果

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy.
PubMed 文献 · Lancet Oncol · 2026-05-14

FAST-Forward是一项在英国97家医院开展的多中心、开放标签、非劣效性3期随机对照试验,纳入4110例pT1-3、pN0-1、M0期浸润性乳腺癌术后患者,按1:1:1随机分配至40 Gy/15次(3周)、27 Gy/5次(1周)或26 Gy/5次(1周)。研究认为26 Gy/5次/1周方案安全有效,可作为标准治疗。

要点

  • 10年随访支持26 Gy/5次/1周作为乳腺或胸壁辅助放疗标准方案

核心结论

  • 长期随访证实26 Gy/5次/1周方案用于乳腺或胸壁辅助放疗安全有效,支持其作为标准治疗。
  • 该方案在腋窝淋巴结放疗场景中的疗效数据令人安心,但样本量限制了该亚组估计的精确性。

研究设计与样本

  • 多中心、开放标签、非劣效性3期随机对照试验,在英国97家医院(47家放疗中心、50家转诊医院)开展。
  • 主要试验2011年11月24日至2014年6月19日入组4110例,排除23例撤回知情者后,10年分析意向治疗人群为4087例。

主要发现

  • 同侧乳腺复发共116例(40 Gy组45例、27 Gy组41例、26 Gy组30例)。
  • 腋窝亚组报告32例局部区域复发。

关键数值与推荐

  • 26 Gy分5次、1周内完成,为全乳或胸壁辅助放疗的推荐标准方案。
  • 40 Gy分15次、3周内完成为对照标准方案。
  • 主要终点为5年同侧乳腺复发非劣效性,本次报告为预设10年意向治疗分析。

临床怎么用

  • 对符合入组条件的早期乳腺癌术后患者,可优先考虑26 Gy/5次/1周的辅助放疗方案。
  • 选择27 Gy/5次方案时需注意其10年中重度正常组织反应发生率高于26 Gy组。
  • 腋窝需要放疗的患者可参考亚组结果,但应知晓其样本量有限。

局限性

  • 研究为开放标签设计,分配未设盲。
  • 腋窝亚组样本量小,单独估计的精确性受限,随访仍在进行中。
  • 10年正常组织反应分析的分母小于总体意向治疗人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: FAST-Forward aimed to identify a 1-week adjuvant radiotherapy schedule for early-stage breast cancer that was as safe and efficacious as the standard 3-week schedule of 40 Gy in 15 fractions over 3 weeks. Primary analysis showed non-inferiority of 5-year ipsilateral breast recurrence for 26 Gy and 27 Gy in five fractions over 1 week, with 26 Gy also having similar results to 40 Gy for normal tissue effects. Here, we report 10-year outcomes of the FAST-Forward trial and 5-year efficacy outcomes of a substudy assessing the approach in patients requiring axillary treatment. METHODS: FAST-Forward is a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial done at 97 hospitals (47 radiotherapy centres and 50 referring hospitals) in the UK. Patients aged 18 years or older with invasive carcinoma of the breast (pT1-3, pN0-1, M0) after breast conservation surgery or mastectomy were eligible. We randomly allocated patients (in a 1:1:1 ratio with random permuted blocks, stratified by radiotherapy centre) to either 40 Gy in 15 fractions (over 3 weeks), 27 Gy in five fractions (over 1 week), or 26 Gy in five fractions (over 1 week) to the whole breast or chest wall. Allocation was not masked because of the nature of the intervention. The primary endpoint was non-inferiority of ipsilateral breast recurrence at 5 years. Here, we report the planned 10-year analysis assessed in the intention-to-treat population (all participants who were randomly assigned and consented for use of data). We also report a planned intention-to-treat analysis of a subsequent substudy assessing 5-year efficacy of the same schedules in patients meeting the study criteria but requiring axillary treatment. The clinical trial was registered with ISRCTN (ISRCTN19906132); the main trial is complete, follow-up of the substudy cohort is ongoing. FINDINGS: Between Nov 24, 2011, and June 19, 2014, 4110 participants were enrolled in the main FAST-Forward trial. 23 withdrew consent for data use and were excluded and 4087 participants were included in the intention-to-treat population for this 10-year analysis. Participants were randomly assigned to 40 Gy (n=1358), 27 Gy (n=1362), or 26 Gy (n=1367). Median follow-up was 10·1 years (IQR 10·0-10·2). Ipsilateral breast recurrence was reported for 116 participants (45 in the 40 Gy group, 41 in the 27 Gy group, and 30 in the 26 Gy group), with 10-year cumulative incidence of 3·6% (95% CI 2·7-4·9) for the 40 Gy group, 2·9% (2·1-4·0) for the 27 Gy group, and 2·1% (1·5-3·1) for the 26 Gy group. 10-year clinician-reported moderate or marked breast or chest wall effects occurred in 100 (13·1%) of 765 participants in the 40 Gy group, 157 (19·3%) of 814 in the 27 Gy group, and 111 (14·4%) of 770 in the 26 Gy group. Between April 11, 2016, and Oct 2, 2018, 469 participants enrolled in the nodal substudy, 466 of which were included in intention-to-treat analyses. Median follow-up was 7·0 years (IQR 6·2-7·1) and 32 locoregional recurrences were reported. INTERPRETATION: Long-term follow-up confirms that 26 Gy in five fractions over 1 week is safe and efficacious for adjuvant radiotherapy to the breast or chest wall, supporting its use as a standard of care. Efficacy data for this schedule in the axillary nodal radiotherapy setting are reassuring; however, sample size limits precision of estimation for this subgroup on its own. FUNDING: UK National Institute for Health and Care Research.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Brunt AM, Cafferty FH, Kirby AM, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy. Lancet Oncol. 2026. PMID: 42134381. doi:10.1016/S1470-2045(26)00076-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。